# OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

> **NCT01600807** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Dana-Farber Cancer Institute**

## Conditions studied

- Pancreatic Cancer, Metastatic

## Interventions

- **DRUG:** Gemcitabine, Erlotinib, OSI-906
- **DRUG:** Gemcitabine, Erlotinib

## Key facts

- **NCT ID:** NCT01600807
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was pending major changes and was on hold, pending activation; administratively withdrawn; will be submitted as a new protocol if study is revised.
- **Last updated:** 2013-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01600807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01600807, "OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01600807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*